Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE ...

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth potential through 2029. Read why I rate KROS as a Hold.

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, ...

Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company adopted a poison pill plan ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.

Analysts fell to the sidelines weighing in on Keros Therapeutics (KROS – Research Report) and Illumina (ILMN – Research Report) with neutral ...

Keros, which had a market capitalization of around $396 million based on Wednesday's closing price, said it will look at a range of options, including a sale or other business combination, continued ...

Truist lowered the firm’s price target on Keros Therapeutics (KROS) to $25 from $43 and keeps a Buy rating on the shares as part of a broader ...

Keros has engaged Goldman Sachs & Co (NYSE: GS ). LLC as its financial advisor and Cooley LLP as legal counsel to assist with the strategic review process. Additional details about the rights plan ...

Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS) ...